SOURCE: CannaPharmaRx, Inc.

CannaPharmaRx, Inc. Logo

January 27, 2015 08:58 ET

CannaPharmaRx Engages Pharmaceutical Industry Drug Delivery Technology Expert Mario A. Gonzalez, Ph.D.

CARNEYS POINT, NJ--(Marketwired - January 27, 2015) - CannaPharmaRx, Inc. (OTCQB: GDHC), the New Jersey-based pharmaceutical company, has announced the signing of a consultancy agreement with Mario A. González, PhD, President and Chief Executive Officer of P'Kinetics International, Inc., a consulting firm specializing in pharmaceutical product development and pharmacokinetics research.

"Mario brings a wealth of knowledge and experience to help CannaPharmaRx innovate the promising cannabinoids under consideration for development by our R&D and commercialization teams," said Gerry Crocker, CEO of CannaPharmaRx.

CannaPharmaRx believes identifying the best route of administration for cannabinoids will lead to novel drug delivery technologies and in turn will be instrumental in mitigating targeted disease states under CannaPharmaRx R & D Pipeline Therapeutic Portfolio.

Dr. Gonzalez was among the scientists who applied and formulated the concept of "Zero Order" kinetics of delivery for theophylline in the treatment of asthma thus resulting in stable steady-state plasma levels with minimal fluctuation. He has also successfully participated in formulating the clinical programs for several Transdermal NDAs.

"I am looking forward to working with the CannaPharmaRx team in identifying and designing new drug delivery systems for the safe and effective delivery of products from the growing body of cannabinoid candidates," said Dr. Gonzalez.

About Dr. Gonzalez
Dr. Gonzalez is an Adjunct Professor at the University of Florida, College of Pharmacy. Dr. Gonzalez's research has concentrated on the pharmacokinetic and pharmacodynamics evaluation of extended release oral and transdermal drug delivery systems and in vitro/in vivo correlations.

His industry experience includes but is not limited to previous positions as President of GloboMax Americas and Director of Biopharmaceutics and Pharmacokinetics at Schering-Plough Research, Miami. He also served on the organizing committees of the first four AAPS/FDA SUPAC workshops and was Co-Chair of the organizing committee for the first Pharmaceutical Congress of the Americas.

Academic experience includes serving on the Pharmacy faculty at Purdue University with teaching and graduate research responsibilities in clinical pharmacokinetics. He has been active in the American Association of Pharmaceutical Scientists since its inception. He is also a member of the Controlled-Release Society, and the American College of Clinical Pharmacology.

Dr. Gonzalez was appointed to the USP Biopharmaceutics Expert Committee for 2005-2010, the Dosage Forms Expert Committee for 2010-2015, and was elected as a Fellow in Clinical Pharmacology by the American College of Clinical Pharmacology. 

About CannaPharmaRx
Our purpose is to innovate to bring cannabinoid-based therapies to market that improve patients' lives. R&D is at the heart of our mission as we work to transform advanced science and technologies into the therapies that matter most. Our executive management team has over 100 years of combined pharmaceutical industry experience developing and marketing prescription products. www.CannaPharmaRx.com 

Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated," and "intend," among others. These forward-looking statements are based on CannaPharmaRx's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical products under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. CannaPharmaRx does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in CannaPharmaRx's private placement agreement and Form 10-Q as of September 30, 2014 (Unaudited) and other periodic reports filed with the Securities and Exchange Commission.

Contact Information